Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001665356 | SCV001872710 | pathogenic | not provided | 2024-02-13 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Ambry Genetics | RCV004039558 | SCV004960034 | uncertain significance | Inborn genetic diseases | 2024-02-14 | criteria provided, single submitter | clinical testing | The c.134A>G (p.H45R) alteration is located in exon 2 (coding exon 2) of the NAA15 gene. This alteration results from an A to G substitution at nucleotide position 134, causing the histidine (H) at amino acid position 45 to be replaced by an arginine (R). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is highly conserved in available vertebrate species. This missense alteration is located in a region that has a low rate of benign missense variation (Lek, 2016; Firth, 2009). This alteration is predicted to be deleterious by in silico analysis. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Clinical Genetics Laboratory, |
RCV002291001 | SCV002583453 | likely pathogenic | Intellectual disability, autosomal dominant 50 | 2022-05-02 | no assertion criteria provided | clinical testing |